Market research
 

THET PAING SOE’S operating culture alongside talented, well-trained and experienced personnel, our sales team has steered its course through vast network of distribution pipelines throughout Myanmar.



On a regular basis, our professional sales representatives visit our customers to fulfill their needs not only by collecting orders but also by sharing useful and updated information as well.

Regulatory Affairs
• Regulatory Affairs services
• Updated laws and health regulations
• PV reports


We can handle and provide Regulatory Affairs services to our valued partners who are in need. In addition, updated laws and health regulations and Pharmacovigilance reports could also be provided by our Regulatory Affairs Department.

 

 
 
Marketing Management

THET PAING SOE has its core marketing team with enough knowledge & skills through which it can provide all clinicians with complete, accurate, comprehensive and impartial information regarding pharmaceuticals.

Market research
 


As part of the requirements of marketing management, we conduct market research in order to make sure understanding of the market situation and consumer’s behavior.
Nationwide Distribution
 


We have our own wholesales & retail sales outlets in Yangon & Mandalay. Through these outlets as well as our Van Sales, we offer a nationwide distribution designed to cover important parts of the country.

We provide the efficient delivery service within 24 hours after receiving an order and also serve an urgent delivery in order to fulfill customers’ special needs.

Logistics
  • • Application for Import License
  • • Customs clearance
  • • Payment remittance
All importation procedures: Application of IL at the Ministry of Commerce, Customs clearance on the product arrival and payment remittance to the related banks are performed by our Logistics Team.
 

PENTAXIM

pentaxim

CONTENTS

Adsorbed diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis vaccine and conjugate Haemophilus influenzae type b vaccine.

PRESENTATION

Prefilled syringe (powd and susp for inj) 0.5 mL x 1's.

DESCRIPTION

Each 0.5-mL dose after reconstitution contains diphtheria toxoid ³30 iu, tetanus toxoid ³40 iu, Bordetella pertussis antigens (toxoid 25 mcg, filamentous haemagglutinin 25 mcg), inactivated type 1 poliomyelitis virus 40 DU*+, inactivated type 2 poliomyelitis virus 8 DU*+, inactivated type 3 poliomyelitis virus 32 DU*+, Haemophilus influenzae type b polysaccharide conjugated with tetanus protein 10 mcg.

*DU: D antigen unit.

+or equivalent antigenic quantity determined by a suitable immunochemical method.

Pentaxim also contains the following excipients: Saccharose, tromethamol, aluminium hydroxide, Hanks medium (without phenol red), acetic acid and/or sodium hydroxide for pH adjustment, formaldehyde, phenoxyethanol and water for injections.

INDICATIONS

Protection against diphtheria, tetanus, pertussis, poliomyelitis; invasive infections due to the Haemophilus influenzae type b bacterium (eg, meningitis, septicemia, etc) in children from 2 months.

Pentaxim does not protect against infections caused by other types of Haemophilus influenzae nor against meningitis due to other microorganisms.

DOSAGE & ADMINISTRATION

Primary Vaccination: 3 injections at 1- to 2-month intervals from 2 months of age.

Booster Vaccination: 1 injection within the 2nd year of life.

Administration: Pentaxim should be administered IM. Administration should preferably be performed in the anterolateral side of the thigh (middle 3rd).

CONTRAINDICATIONS

Hypersensitivity to any of the components of Pentaxim or to pertussis vaccines (acellular or whole cell pertussis) or an allergic reaction after injection of a vaccine containing the same substances.

Patients with evolving encephalopathy (cerebral lesions); who suffered from encephalopathy (cerebral lesions) within 7 days of a previous dose of a pertussis vaccine (acellular or whole cell pertussis); fever or an acute disease (the vaccination must be postponed.

PRECAUTIONS

Make sure the vaccine is not injected by the intravascular route (the needle must not penetrate a blood vessel) nor by the intradermal route.

Hypersensitivity to glutaraldehyde, neomycin, streptomycin and polymyxin B, as these substances are used during the manufacturing process.

History of febrile convulsions not related to a previous vaccine injection; in this case, it is particularly important that the temperature be monitored in the 48 hrs following vaccination and that antipyretic treatment be regularly administered to help reduce fever for 48 hrs.

If any of the following events are known to have occurred in temporal relation to receipt of vaccine (the decision to give further doses of pertussis-containing vaccine should be carefully considered): Fever ³40°C within 48 hrs not due to another identifiable cause.

Collapse or shock-like state with hypotonic-hyporesponsive episode (drop in energy) within 48 hrs of vaccination.

Persistent, inconsolable crying lasting ³3 hrs, occurring within 48 hrs of vaccination.

Convulsions with or without fever, occurring within 3 days of vaccination.

Medical problems or allergic reactions; Guillain-Barre syndrome (abnormal sensitivity, paralysis) or brachial neuritis (paralysis, diffuse pain in the arm and shoulder) following receipt of a prior vaccine containing tetanus toxoid (vaccine against tetanus), the decision to give any further vaccine containing tetanus toxoid should be evaluated by the physician.

Oedematous reactions occurring in the lower limbs after injection of a vaccine containing the Haemophilus influenzae type b valence, the 2 vaccines, diphtheria-tetanus-pertussis-poliomyelitis vaccine and the Haemophilus influenzae type b conjugate vaccine should be administered in 2 separate injection sites and on 2 different days.

If the patient follows a treatment that suppresses the immune defenses or in case of immunodeficiency, the immune response to the vaccine may be decreased. It is then recommended to wait until the end of the treatment or disease before vaccinating. Nevertheless, vaccination of subjects with chronic immunodeficiency eg, HIV infection is recommended even if the antibody response may be limited.

Pentaxim does not protect against invasive diseases caused by serotypes other than Haemophilus influenzae type b, nor against meningitis due to other microorganisms.

SIDE EFFECTS

The most common reactions are irritability, local reactions at injection site eg, redness and induration >2 cm. These signs and symptoms usually occur within 48 hrs following the vaccination and may continue for 48-72 hrs. They resolve spontaneously without requiring specific treatment.

The following side effects have been reported: Erythema, induration, pain at the injection site; redness and oedema (swelling) ³5 cm at the injection site; fever sometimes above 40°C.

Diarrhoea, vomiting, loss of appetite.

Somnolence, convulsion with or without fever, hypotonic-hyporesponsive episodes (hypotonic episode, drop in energy, hyporesponsiveness, drop in awareness).

Nervousness, irritability, insomnia or sleep disturbances, abnormal crying, prolonged inconsolable crying.

Allergy-like symptoms eg, rash, erythema and urticaria.

Furthermore, during the administration of Haemophilus influenzae type b containing vaccines, oedematous reactions (swelling) affecting the lower limbs have been reported.

These reactions are sometimes accompanied by fever, pain and crying. They are not accompanied by cardiorespiratory signs.

Potential side effects (ie, they have not been reported directly with Pentaxim, but with other vaccines containing one or more of the antigenic constituents of Pentaxim) are the following: Guillain-Barre syndrome (abnormal sensitivity, paralysis) and brachial neuritis (paralysis, diffuse pain in the arm and shoulder) following administration of a vaccine containing tetanus toxoid.

Oedema (swelling) >5 cm that may spread over the entire limb after administration of acellular pertussis-containing vaccines. This reaction generally occurs within 24-72 hrs after vaccination and resolves without treatment within 3-5 days. The risk seems to be greater following the 4th and 5th doses.

CAUTIONS FOR USAGE

Instructions for Use and Handling: For syringes without attached needles, the separate needle must be fitted firmly to the syringe, rotating it by a one-quarter turn.

Reconstitute the vaccine by injecting the suspension of the combined diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine into the vial of the Haemophilus influenzae type b conjugate vaccine.

Shake until complete dissolution of the powder. The whitish-turbid aspect of the suspension after reconstitution is normal.

The vaccine must be injected immediately after reconstitution.

Do not use Pentaxim if an abnormal colour appears or if there is a presence of foreign particles.

STORAGE

Store in a refrigerator (2-8°C). Do not freeze.

Shelf-Life: 3 years.